Lymphopenia during chemoradiation-foe or friend

Area of Science:

• Oncology
• Clinical Research
• Immunology

Background:

• Severe lymphopenia is a known poor prognostic factor in cancer treatment.
• Limited prospective data exists on its impact on outcomes in locally advanced head and neck cancer (HNC).

Purpose of the Study:

• To investigate the association between severe lymphopenia and patient outcomes in locally advanced HNC.
• To identify risk factors associated with the development of severe lymphopenia.

Main Methods:

• Analysis of a randomized study comparing cisplatin-radiation with nimotuzumab cisplatin-radiation in 536 HNC patients.
• Kaplan-Meier and Cox regression analyses assessed the impact of grade 4 lymphopenia on progression-free survival (PFS), locoregional control (LRC), and overall survival (OS).
• Binary logistic regression identified factors associated with severe lymphopenia development.

Main Results:

• Lymphopenia occurred in 97.7% of patients; 13.7% had grade 4 (severe) lymphopenia.
• No significant association was found between severe lymphopenia and PFS (HR 0.797, p=0.208), LRC (HR 0.81, p=0.337), or OS (HR 0.76, p=0.11).
• Male gender was significantly associated with the development of severe lymphopenia.

Conclusions:

• Severe lymphopenia does not significantly affect PFS, LRC, or OS in locally advanced HNC patients.
• Gender is the sole identified risk factor linked to severe lymphopenia in this cohort.